Saturday 17 October 2026
Export AMRN’s income statement to Excel — free account
Amarin Corporation PLC
AMRN Healthcare Drug Manufacturers General
Amarin Corporation PLC’s revenue for fiscal 2025 (year ended December 2025) was $213.6 million, down 6.55% from fiscal 2024. In the quarter to June 2026, revenue fell 42.0%, EPS grew 45.8% and free cash flow fell 60.2%, each against the same quarter a year earlier.
11.37
0.20
−1.73%
Follow AMRN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.50 | 1.36 | 1.40 | 1.78 | |
P/FCF ratio |
0.00 | 43.21 | 11.86 | 21.35 | |
P/Operating CF |
(26.80) | 18.96 | 47.43 | 50.26 | |
P/B ratio |
0.74 | 0.63 | 0.67 | 0.75 | |
Price to Tangible BV |
0.77 | 0.65 | 0.69 | 0.77 | |
EV/Sales |
0.32 | 0.02 | 0.06 | 0.19 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.28) | 0.77 | 0.52 | 2.27 | |
EV/FCF |
(3.28) | 0.78 | 0.52 | 2.28 | |
Quick Ratio |
2.27 | 2.21 | 2.32 | 2.48 | |
Current Ratio |
3.45 | 3.34 | 3.48 | 3.67 | |
Net Debt/EBITDA |
28.03 | 53.83 | 28.80 | 27.68 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.32 | 0.32 | 0.33 | 0.29 | |
Operating CF/Net income |
1.64 | (12.48) | (0.61) | (0.86) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
8.47% | 10.91% | 10.34% | 11.31% | |
Selling, General and Administrative Expense of Revenue |
39.66% | 40.76% | 46.78% | 52.56% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
3.94% | 3.28% | 5.16% | 4.98% | |
Graham Net Nets |
1.26 | 1.51 | 1.42 | 1.27 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(25.73%) | (13.39%) | (11.83%) | (8.77%) | |
Free Cash Flow Yield |
(6.43%) | 2.31% | 8.43% | 4.68% | |
Revenue per Share |
2.39 | 2.37 | 2.15 | 2.03 | |
Operating CF per Share |
(0.61) | 0.74 | 0.30 | 0.32 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.61) | 0.74 | 0.30 | 0.32 | |
Cash per Share |
13.81 | 14.59 | 14.70 | 15.12 | |
Shareholders Equity per Share |
22.09 | 22.13 | 21.45 | 21.31 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
22.09 | 22.13 | 21.45 | 21.31 | |
Free Cash Flow |
(12.70) | 15.28 | 6.39 | 6.60 | |
Working Capital |
446.10 | 455.42 | 446.37 | 438.56 | |
Net Current Asset Value |
427.41 | 438.39 | 429.67 | 422.01 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
119.98 | 124.56 | 107.39 | 106.02 | |
Average Payables |
38.61 | 42.86 | 46.91 | 31.75 | |
Average Inventory |
204.35 | 180.98 | 171.54 | 167.66 | |
Average Assets |
705.21 | 678.06 | 650.72 | 647.24 | |
Average Common Equity |
495.13 | 472.73 | 461.55 | 454.27 |
Columns are period end dates